åêðáéäåõóçó γ.ν.α.

ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ, ΤΟΜΟΣ 71, ΣΥΜΠΛΗΡΩΜΑ, 2009
473
Pulmonary-vein isolation for atrial fibrillation in patients
with heart failure. N Engl J Med 2008;359:1778-85.
16. Dixit S, Gerstenfeld EP, Ratcliffe SJ, et al. Single procedure
efficacy of isolating all versus arrhythmogenicpulmonary
veins on long-term control of atrial fibrillation:A prospective
randomized study. Heart Rhythm 2008;5:174
–181.
17. Elayi CS, Verma A, Di Biase L, et al. Ablation for longstanding
permanent atrial fibrillation: Results from a
randomized study comparing three different strategies.
Heart Rhythm 2008;5:1658 –1664.
18. Nof E, Luria D, Brass D, et al. Point Mutation in the
HCN4 Cardiac Ion Channel Pore Affecting Synthesis,
Trafficking, and Functional Expression Is Associated With
Familial Asymptomatic Sinus Bradycardia. Circulation.
2007;116:463-470.
19. Ravn LS, Aizawa Y, Pollevick GD, et al. Gain of function
in IKs secondary to a mutation in KCNE5 associated with
atrial fibrillation. Heart Rhythm 2008;5:427–435.
20. van Tintelen JP, Hofstra RM, Katerberg H, et al. High
yield of LMNA mutations in patients with dilated cardiomyopathy
and/or conduction disease referred to
cardiogenetics outpatient clinics. Am Heart J 2007
Dec;154(6):1130-9.
21. Chow Τ, Kereiakes DJ, Onufer G, et al. Οn behalf of
the MASTER Trial Investigators Does Microvolt T-Wave
Alternans Testing Predict VentricularTachyarrhythmias
in Patients With Ischemic Cardiomyopathy and
Prophylactic Defibrillators The MASTER (Microvolt T
Wave Alternans Testing for Risk Stratification of Post-
Myocardial Infarction Patients) Trial. J Am Coll Cardiol
2008;52:1607–15.
22. Gold MR, Costantini O, Poole JE, et al. Role of microvolt
T-wave alternans in assessment of arrhythmia
vulnerab;ility among patients with heart failure and
systolic dysfunction: primary results from the T-wave
alternans sudden cardiac death in heart failure trial
substudy. Circulation 2008;118:2022-8.
23. Heart Rhythm UK Familial Sudden Death Syndromes
Statement Development Group. Clinical indications
for genetic testing in familial sudden cardiac death
syndromes: an HRUK position statement. Heart 2008;
94;502-507.
24. Wachtell K, Okin PM, Olsen MH, et al. Regression of
ECG left ventricular hypertrophy during antihypertensive
therapy and reduction in sudden cardiac death: the LIFE
study. Circulation. 2007 Aug 14;116(7):700-5.
25. Albert CM, Rosenthal L, Calkins H, et al. Driving and
Implantable Cardioverter-Defibrillator Shocks for Ventricular
Arrhythmias Results From the TOVA Study. J
Am Coll Cardiol 2007;50:2233–40.
26. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence
and frequency of arrhythmias in hypertrophic cardiomyopathy
in relation to delayed enhancement on
cardiovascular magnetic resonance. J Am Coll Cardiol
2008;51:1369 –74.
27. Beeres, MD S, Zeppenfeld K, Bax JJ, et al. Electrophysiological
and arrhythmogenic effects of intramyocardial
bone marrow cell injection in patients with chronic
ischemic heart disease. Heart Rhythm 2007;4:257–
265.
28. Sesselberg HW, Moss AJ, McNitt S, et al. Ventricular
arrhythmia storms in postinfarction patients with implantable
defibrillators for primary prevention indications: A
MADIT-II substudy. Heart Rhythm 2007;4:1395–1.
29. Cuoco FA, Spencer III WH, Fernandes VL, et al. Implantable
Cardioverter-Defibrillator Therapy for Primary Prevention
of Sudden Death After Alcohol Septal Ablation
of Hypertrophic Cardiomyopathy. J Am Coll Cardiol
2008;52:1718–23.
30. Wilkoff BL, Williamson BD, Stern RS, et al. Strategic
Programming of Detection and Therapy Parameters in
Implantable Cardioverter-Defibrillators Reduces Shocks
in Primary Prevention Patients Results From the PREPARE
(Primary Prevention Parameters Evaluation) Study. J Am
Coll Cardiol 2008;52:541–50.
31. No Benefit From Defibrillation Threshold Testing in the
SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)
Blat JA, Poole JE, Johnson WG, et al. for the SCD-HeFT
Investigators. J Am Coll Cardiol 2008;52:551–6.
32. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic
importance of defibrillator shocks in patients with heart
failure. N Engl J Med 2008;359:1009-17.
33. Dorian P, Al-Khalid HR, Hohnloser S, et al. Azimilide
Reduces Emergency Department Visits and Hospitalizations
in Patients With an Implantable Cardioverter-
Defibrillator in a Placebo-Controlled Clinical Trial. J Am
Coll Cardiol 2008;52:1076–83.
34. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic
catheter ablation for theprevention of defibrillator
therapy. N Engl J Med 2007;357:2657–2665.
35. Yamada T, Murakami Y, Yoshida N, et al. Preferential
conduction across the ventricular outflow septum in
ventricular arrhythmias originating from the aortic sinus
cusp. J Am Coll Cardiol 2007;50:884–89.
36. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine,
an antianginal agent with novel electrophysiological
properties, on the incidence of arrhythmias in patients
with non ST-segment elevation acute coronary syndrome:
results from the Metabolic Efficiency With Ranolazine
for Less Ischemia in Non ST-Elevation Acute Coronary
Syndrome Thrombolysis in Myocardial Infarction 36
(MERLINTIMI36) randomized controlled trial. Circulation
2007;116:1647–1652.
37. Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased
mortality after dronedarone therapy for severe heart
failure. New Engl J Med 2008;358:2678-2687.
38. Benito B, Brugada R, Berruezo A, et al. A mutation in
the sodium channel responsible for the association of
long-QT syndrome and familial atrial fibrillation. Eur